An exploratory open-label trial of ziprasidone for the treatment of behavioral and psychological symptoms of dementia
| Autor: | Gleida de Oliveira Lança, Melissa Guarieiro Ramos, Fábio Lopes Rocha, Cláudia Hara, Francisca Magalhães Scoralick, Gustavo Guimarães Kascher, Milena Antunes Santos |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
medicine.medical_specialty medicine.drug_class Gastrointestinal Diseases Cognitive Neuroscience Atypical antipsychotic Disorders of Excessive Somnolence Drug Administration Schedule Piperazines law.invention Randomized controlled trial law medicine Dementia Humans Ziprasidone Parkinson Disease Secondary Psychiatry Ziprasidona Aged Aged 80 and over business.industry Mental Disorders Cognitive disorder Middle Aged medicine.disease Psychiatry and Mental health Thiazoles Tolerability Female Geriatrics and Gerontology Open label business medicine.drug Clinical psychology Antipsychotic Agents |
| Zdroj: | Dementia and geriatric cognitive disorders. 22(5-6) |
| ISSN: | 1420-8008 |
| Popis: | Objective: To evaluate the efficacy and tolerability of ziprasidone in behavioral and psychological symptoms of dementia. Method: A 7-week open-label trial of ziprasidone. Results: Of the 25 patients who participated, 15 completed the study. The main reason for discontinuation was adverse events. The mean total Neuropsychiatric Inventory (NPI) score fell significantly from 47.1 ± 17.1 (baseline) to 25.8 ± 17.9 (day 49) (p < 0.01). The NPI caregiver burden showed a significant improvement from 22.6 ± 8.3 at baseline to 11.8 ± 7.3. The most frequent adverse events were somnolence, gastrointestinal symptoms and parkinsonism. Conclusions: Ziprasidone was able to significantly improve distressing non-cognitive symptoms of dementia although adverse effects occurred. Additional large-scale, double-blind, well-controlled studies are necessary to evaluate the use of ziprasidone in this indication. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|